Navigation Links
Despite Oncologists' Willingness to Prescribe Avastin for Treatment of Breast Cancer, the FDA is Likely to Rule Against the Product on February 23
Date:2/11/2008

Seventy-nine Percent of U.S. Oncologists Currently Use Avastin to Treat the

Disease, According to a New Macroview Update from Decision Resources

WALTHAM, Mass., Feb. 11 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, reports that the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against Genentech/Roche's Avastin for first-line treatment of breast cancer in December 2007. According to the new Macroview update, the FDA's ODAC voted 5 to 4 that data are insufficient to recommend Avastin for approval for first-line treatment of metastatic or recurrent breast cancer.

The ODAC said that in the absence of a benefit in overall survival, Avastin's 5.5 month improvement in progression-free survival does not outweigh the risks associated with the drug.

An August 2007 survey by Decision Resources found that a very high rate of oncologists prescribing Avastin off-label to treat metastatic breast cancer.

"In August of 2007, 79 percent of U.S. oncologists were using Avastin to treat breast cancer patients," said Mary Fletcher-Louis., director at Decision Resources. "This prescribing behavior is driven by familiarity with Avastin for colorectal cancer and non-small-cell lung cancer, and by approval of this agent for breast cancer in Europe."

The FDA is not bound by the ODAC vote, and will make its final decision by February 23, 2008. For commentary on the final vote, please contact Elizabeth Marshall at 781-296-2563 to schedule an interview with Dr. Argent-Katwala.

About Macroview from Decision Resources

Macroview is the most up-to-date analysis on events impacting the healthcare industry. The Macroview updates are part of Decision Resources' Pharmaview product line, which offers a thorough analysis of the biopharmaceutical sector from a therapy, industry and company point-of-view.

About Decision Resources

Decision Resources (http://www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Despite polarized opinions, Democrats and Republicans perform same amount of green actions
2. Physicians Still Hopeful About Desmoteplase for the Treatment of Acute Ischemic Stroke Despite Negative Results
3. Herons persist in Chicago wetlands despite exposure to banned chemicals
4. Despite efforts, significant racial disparities in cancer therapy still exist
5. Coshocton County Memorial Hospital RNs to Strike Despite Hospitals Claim of Financial Hardship
6. Miscarriage myths persist despite prevalence of medical information
7. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
8. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
9. A Full and Long Life, Despite Diabetes
10. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
11. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... WV (PRWEB) , ... February 22, 2017 , ... ... awarded a contract to Quality Insights to help small practices in Delaware, New ... Payment Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... communications company, launched a new media platform connecting healthcare technology professionals and other ... be followed by a quarterly publication starting on March 1, announced Michael J. ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pet obesity in the U.S. continued to steadily ... the Association for Pet Obesity Prevention (APOP). During the ninth annual survey, APOP also ... the benefits of corn and grains, value of raw and organic diets, and the ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... A research report by Arcview Market Research focused on cannabis ... changing landscape of the legal market reveals that regulated cannabis sales ... , a 30% increase from 2015. According to the research ... 2021 representing a 26 percent compound annual growth rate. The use ... Canada is gradually becoming more mainstream thanks ...
(Date:2/22/2017)... LONDON , Feb. 22, 2017  Based ... therapy market, Frost & Sullivan recognizes SnooZeal, Inc. ... SnooZeal is a highly innovative product that intelligently ... training the tongue muscles through the clinically proven ... over-the-counter (OTC) status, SnooZeal is one of the ...
(Date:2/22/2017)... Feb 22, 2017 Research and Markets ... Devices Market (Thermometers - Digital, Infrared, Mercury; Trend Indicator):Analysis By Region, ... ... Market is forecasted to grow at a CAGR of 5.33% during ... prevalence of infectious diseases along with surging demand of digital thermometer. ...
Breaking Medicine Technology: